8-K: ENDRA Life Sciences Announces Q4 and Full-Year 2024 Results and Strategic Shift Towards Metabolic Disease Market

ENDRA Life Sciences reported its Q4 and full-year 2024 financial results, highlighting a strategic pivot towards leveraging its TAEUS technology for early detection and management of metabolic diseases, particularly in patients using GLP-1 therapies.

Summary

• ENDRA Life Sciences reported financial results for the fourth quarter and full year ended December 31, 2024.
• The company is shifting its focus to using its TAEUS technology as a biomarker solution for metabolic diseases, especially in patients treated with GLP-1 drugs.
• In Q4 2024, cash used in operations decreased to $1.5 million, compared to $2.2 million in Q4 2023.
• Operating expenses in Q4 2024 were $4.3 million, up from $1.5 million in the same period last year, due to one-time non-cash items.
• The net loss for Q4 2024 was $4.2 million, compared to $1.5 million in Q4 2023.
• For the full year 2024, cash used in operations decreased to $7.4 million from $9.5 million in 2023.
• Total operating expenses in 2024 were $10.8 million, slightly higher than $10.5 million in 2023, due to a $2.3 million inventory valuation charge.
• The company reported a net loss of $11.5 million for 2024, compared with a net loss of $10.1 million in 2023.
• As of December 31, 2024, ENDRA had $3.2 million in cash and cash equivalents.
• ENDRA is refining the TAEUS Liver device for a De Novo submission to the FDA, including enhancements to hardware and software.
• A multi-site pilot study involving over 110 subjects is underway to assess TAEUS liver fat measurement capabilities against MRI-PDFF.
• The company intends to conduct a hypothesis-driven, statistically powered prospective clinical trial with approximately 250 subjects for the De Novo submission.
• ENDRA implemented cost reductions, decreasing monthly cash burn to an average of $0.5 million in Q4 2024 and expecting $0.35 million per month for Q2 and Q3 2025.
• The company is targeting pharmaceutical companies, concierge medical practices, bariatric clinics, and primary care practices as new customer segments.
• ENDRA plans to offer TAEUS through a monthly subscription-based sales model.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported increased losses, it is actively addressing its financial situation by reducing cash burn and strategically pivoting to a larger market. The progress in clinical data collection and engagement with the FDA are also positive signs.

Positives

• ENDRA is strategically shifting to a larger and more viable market opportunity in metabolic diseases.
• The company has significantly reduced its cash burn, demonstrating improved financial discipline.
• Clinical data collection is progressing with a multi-site pilot study.
• The company is engaging with the FDA to align on the pivotal trial design for the De Novo submission.
• A subscription-based sales model is planned to increase customer adoption.

Negatives

• The net loss increased for both Q4 and the full year 2024, although this was largely due to one-time, non-cash charges.
• Operating expenses increased in Q4 2024 due to a non-cash inventory valuation charge.
• The company had a net loss of $11.5 million for 2024.
• The company had $3.2 million in cash and cash equivalents as of December 31, 2024, which may necessitate future capital raises.

Risks

• The ability to raise additional capital is crucial for ENDRA to continue as a going concern.
• Obtaining FDA approval for the TAEUS Liver device is subject to regulatory uncertainties.
• Market acceptance of TAEUS technology and competition in the industry pose risks.
• The company's dependence on its senior management team is a potential risk factor.
• The company's ability to maintain compliance with Nasdaq listing standards and remain listed on a securities exchange is a potential risk factor.

Future Outlook

ENDRA is focused on advancing its TAEUS Liver device through the FDA regulatory process, with a planned De Novo submission supported by a multicenter clinical trial. The company expects to further reduce its cash burn and is targeting new customer segments in the metabolic disease market. They also plan to expand TAEUS applicability beyond liver health.

Management Comments

• Alexander Tokman, Chief Executive Officer of ENDRA, stated that there is an unmet need for a cost-effective, simple-to-use and accurate point-of-care test as GLP-1 therapies are increasingly used.
• Management believes TAEUS is uniquely positioned to fill this gap and meet the needs of providers, patients and payers.

Industry Context

The strategic shift towards the metabolic disease market aligns with the growing prevalence of conditions like obesity, type 2 diabetes, and cardiovascular disease, and the increasing use of GLP-1 therapies. The need for non-invasive, cost-effective diagnostic tools for liver health is significant, especially in the context of metabolic dysfunction-associated steatohepatitis (MASH).

Comparison to Industry Standards

• The gold standard for liver fat measurement is MRI-PDFF, which is expensive and not readily accessible.
• ENDRA aims to provide a point-of-care alternative to MRI-PDFF, similar to how a blood pressure cuff is used for hypertension.
• Competitors in the liver diagnostics space include companies developing non-invasive tests based on biomarkers or imaging techniques, but few offer a point-of-care solution like TAEUS.
• The subscription-based sales model is common in the medical device industry to lower the initial cost barrier for adoption.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and strategic shift.
• Employees may be affected by cost reductions and changes in the company's focus.
• Customers (pharmaceutical companies, medical practices, clinics) may benefit from the availability of a cost-effective diagnostic tool.
• Patients may benefit from earlier detection and management of metabolic diseases.
• Suppliers may be impacted by changes in the company's product development and manufacturing plans.

Next Steps

• Continue collecting clinical data to support the De Novo regulatory filing with the FDA.
• Refine the TAEUS Liver device design for improved accuracy, usability, and scalability.
• Conduct a multicenter clinical trial with approximately 250 subjects.
• Engage with the FDA to finalize the trial design and statistical analysis plan.
• Develop additional high-value applications for TAEUS technology beyond liver health.
• Implement the subscription-based sales model for TAEUS.

Key Dates

Keywords

TAEUS, Liver disease, Metabolic diseases, GLP-1, De Novo submission, FDA, Financial results, Clinical trial, Steatosis, Cash burn